1
Return

Influenza Virus-Like Particles Displaying Leishmania donovani Promastigote Surface Antigen Induce Cross-Protective Immunity

delete2026-06-26
delete0
PRE
AI
K
Keon-Woong Yoon
K
Ki Back Chu
S
Su In Heo
H
Hyeon-Woo Nam
J
Ji-Hyun Lee
J
Jie Mao
M
Manish Kumar Singh
S
Sung Soo Kim
权福实 (Fu‐Shi Quan)
DOI:10.1021/acsinfecdis.6c00156delete
deleteOriginal
deleteOriginal request for help
deleteShare
deleteSave
Abstract

Abstract

En 中文
Virus-like particles expressing the Promastigote surface antigen (PSA) of Leishmania donovani have shown great potential as a vaccine candidate against L. donovani infection. However, their potential as a cross-protective leishmaniasis vaccine candidate has remained unexplored. In this study, we generated the L. donovani PSA-expressing influenza virus-like particle vaccines and evaluated their cross-protective potential against Leishmania amazonensis infection in mice. Virus-like particles expressing the L. donovani PSA on influenza M1 protein (LdPSA-VLP) were self-assembled in insect cells using the baculovirus expression system. To evaluate the efficacy of our LdPSA-VLP vaccine, mice were subcutaneously immunized and then challenged with virulent L. amazonensis. LdPSA-VLP immunization elicited L. amazonensis antigen-specific IgG antibodies. Upon challenge infection with mCherry-expressing L. amazonensis, L. amazonensis-specific antibody-secreting cell responses, germinal center B cell, memory B cell, and CD4+/CD8+ T cell responses were markedly enhanced in immunized mice. Footpad inflammation was significantly inhibited, as indicated by decreased proinflammatory cytokine production. LdPSA-VLP provided cross-protection against L. amazonensis by reducing footpad swelling and parasite burden in the footpads. Our findings indicate that LdPSA-VLPs could serve as promising cross-protective vaccine candidates against cutaneous leishmaniasis.
Keywords:
Immunology
Infectious diseases
Peptides and proteins
Rodent models
Vaccination
Leishmania amazonensis
Leishmania donovani
promastigote surface antigen
vaccine
virus-like particles

Journal

ACS Infectious Diseases cover
ACS Infectious Diseases
IF:
3.8
Papers:
2.4K
Citations:
6.9K

Organization

Y
yale university school of medicine
Scholars:
336
Papers: 80
Citations: 0
X
Xiamen Innovax Biotech Co., Ltd.
Scholars:
7
Papers: 3
Citations: 0
I
inje university
Scholars:
6.5K
Papers: 6.0K
Citations: 2
K
Kyung Hee University
Scholars:
2.5K
Papers: 989
Citations: 639
Cited Papers

Cited Papers

Citing Papers

Citing Papers